Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

482
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
482
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

822
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
822
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

415
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
415
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

469
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
469
Pulmonary Embolism III: Nursing Management01:27

Pulmonary Embolism III: Nursing Management

756
A pulmonary embolism occurs when a thrombus, amniotic fluid, tumor tissue, fat, or air embolus blocks one or more pulmonary arteries. Effective nursing management and patient education are crucial for improving outcomes and preventing recurrence.Nursing management starts with obtaining a comprehensive patient history, particularly noting any history of deep vein thrombosis (DVT). Assess for clinical manifestations, including dyspnea, chest pain, crackles, heart murmurs, and signs of right-sided...
756
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

749
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
749

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Maternal satisfaction and perceived quality of care during childbirth in a tertiary care Italian Obstetrics Unit: a cross-sectional study.

BMC pregnancy and childbirth·2026
Same author

TP53 Mutations Unfavorably Impact the Outcomes of Myelofibrosis Patients with or Without Hematopoietic Stem Cell Transplantation: A Single-Center Study and Meta-Analysis.

International journal of molecular sciences·2026
Same author

A dynamic prognostic model for Polycythemia Vera long-terms outcomes in patients treated with Ruxolitinib.

Blood advances·2026
Same author

Extracellular Vesicle-Associated IL4 Displays Enhanced Anti-Inflammatory Properties in Microglial Cells.

Journal of extracellular biology·2026
Same author

Assessment of the Performance of Siemens Scopio Digital Morphology on Bone Marrow Aspirates in Onco-Hematology.

International journal of laboratory hematology·2026
Same author

A nationwide Italian GIMEMA survey on tandem autologous stem cell transplantation for newly diagnosed multiple myeloma patients treated with daratumumab, bortezomib, thalidomide and dexamethasone.

Haematologica·2026

Related Experiment Video

Updated: May 2, 2026

Author Spotlight: Advancing Cancer Associated Thrombosis Research in Rodent Models
04:40

Author Spotlight: Advancing Cancer Associated Thrombosis Research in Rodent Models

Published on: January 5, 2024

3.2K

Venous thromboembolism in multiple myeloma.

Valerio De Stefano1, Tommaso Za1, Elena Rossi1

  • 1Institute of Hematology, Department of Medical Sciences, Catholic University, Rome, Italy.

Seminars in Thrombosis and Hemostasis
|March 7, 2014
PubMed
Summary

Multiple myeloma patients face a higher risk of venous thromboembolism (VTE). Antithrombotic prophylaxis, including low-molecular-weight heparin, can significantly reduce VTE incidence in these patients.

More Related Videos

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

6.1K
Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

12.5K

Related Experiment Videos

Last Updated: May 2, 2026

Author Spotlight: Advancing Cancer Associated Thrombosis Research in Rodent Models
04:40

Author Spotlight: Advancing Cancer Associated Thrombosis Research in Rodent Models

Published on: January 5, 2024

3.2K
Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

6.1K
Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

12.5K

Area of Science:

  • Hematology
  • Oncology
  • Thrombosis Research

Background:

  • Multiple myeloma (MM) significantly increases the risk of venous thromboembolism (VTE).
  • VTE incidence in MM patients ranges from 8 to 22 per 1,000 person-years.
  • Risk factors for VTE in MM include patient-related, disease-related, and treatment-related elements.

Purpose of the Study:

  • To review the risk factors and incidence of VTE in multiple myeloma.
  • To evaluate the efficacy of different antithrombotic prophylaxis strategies.

Main Methods:

  • Literature review of studies on VTE in multiple myeloma.
  • Analysis of risk factors associated with disease and treatments.
  • Evaluation of prophylactic antithrombotic agents.

Main Results:

  • Chemotherapeutic agents like doxorubicin double the baseline VTE risk.
  • Combinations of thalidomide or lenalidomide with dexamethasone or chemotherapy increase VTE rates up to 25%.
  • Prophylaxis with low-molecular-weight heparin (LMWH), warfarin, or aspirin reduces VTE rates to 1-8% depending on the treatment.

Conclusions:

  • VTE prophylaxis is crucial for multiple myeloma patients, especially those undergoing specific treatments.
  • Tailoring prophylaxis based on individual risk factors, disease stage, and potential complications like thrombocytopenia or renal insufficiency is recommended.
  • LMWH demonstrates a potential efficacy advantage in VTE prevention, though not statistically significant.